Maravai LifeSciences(MRVI) - 2025 Q1 - Earnings Call Presentation

Financial Performance - Q1 2025 revenue reached $47 million[12] - Nucleic Acid Production (NAP) revenue was $29 million, accounting for 61% of total revenue[49, 50] - Biologics Safety Testing (BST) revenue was $18 million, representing 39% of total revenue[50, 51] - The company reported a GAAP net loss of $53 million[39] - Adjusted EBITDA was -$11 million, with an adjusted EBITDA margin of -23%[39] - Basic and Diluted EPS were both -$0.21, while Adjusted EPS was -$0.08[42] Guidance and Outlook - The company anticipates full-year 2025 revenue to be between $185 million and $205 million[53] - Q2 2025 revenue is projected to be in the range of $45 million to $50 million[53] - Capital expenditures for FY 2025 are expected to be between $15 million and $20 million[47, 54] Business Highlights - The company has 447 CleanCap customers in clinical stage, which is a 15% year-over-year increase[26] - The company has approximately 1,500 total programs, with 30% in clinical and 70% in preclinical stages[26]